Agenus (AGEN) Total Non-Current Liabilities (2010 - 2026)
Agenus (AGEN) posted quarterly Total Non-Current Liabilities of $15.8 million for Q1 2026, down 92.09% year-over-year from $199.4 million in Q1 2025, and up 2.21% quarter-over-quarter from $15.4 million in Q4 2025.
Agenus (AGEN) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Agenus' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $15.8 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 92.09% year-over-year to $15.8 million; the TTM figure through Mar 2026 stood at $15.8 million (down 92.09% YoY), while the FY2025 annual figure was $15.4 million, down 93.16% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $15.8 million, up from $15.4 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $454.4 million in Q2 2022, with the low at $15.0 million in Q3 2025.
- The 5-year median for Total Non-Current Liabilities is $290.9 million (2024), against an average of $268.6 million.
- The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities surged 141.47% in 2022, then tumbled 93.67% in 2025.
- Agenus' Total Non-Current Liabilities stood at $398.9 million in 2022, then slipped by 22.66% to $308.5 million in 2023, then decreased by 26.89% to $225.5 million in 2024, then sank by 93.16% to $15.4 million in 2025, then rose by 2.21% to $15.8 million in 2026.
- Business Quant data shows AGEN's Total Non-Current Liabilities at $15.8 million in Q1 2026, $15.4 million in Q4 2025, and $15.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Agenus | 311.95 Mn | 286.43 Mn | 34.52 Mn | 16.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.08 Mn |
| Mar 31, 2026 | 15.78 Mn |
| Dec 31, 2025 | 15.44 Mn |
| Sep 30, 2025 | 15.04 Mn |
| Jun 30, 2025 | 184.47 Mn |
| Mar 31, 2025 | 199.44 Mn |
| Dec 31, 2024 | 225.53 Mn |
| Sep 30, 2024 | 237.71 Mn |
| Jun 30, 2024 | 290.93 Mn |
| Mar 31, 2024 | 253.83 Mn |
| Dec 31, 2023 | 308.49 Mn |
| Sep 30, 2023 | 327.16 Mn |
| Jun 30, 2023 | 372.52 Mn |
| Mar 31, 2023 | 398.94 Mn |
| Dec 31, 2022 | 398.86 Mn |
| Sep 30, 2022 | 427.55 Mn |
| Jun 30, 2022 | 454.38 Mn |
| Mar 31, 2022 | 439.87 Mn |
| Dec 31, 2021 | 464.38 Mn |
| Sep 30, 2021 | 433.90 Mn |